Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
Arthur Kavanaugh(University of California System), Philip J. Mease(Providence College), Dafna D. Gladman(Toronto Western Hospital), Georg Schett(Karolinska University Hospital), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Maria Paris(Amgen (United States)), B. Guérette, Lichen Teng(Harbin Medical University), Nikolay Delev(Bristol-Myers Squibb (Sweden))
Cited by 80
Related Papers
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k